Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Nubeqa® (darolutamide) – Expanded indication
August 5, 2022 - The FDA announced the approval of Bayer’s Nubeqa (darolutamide), for the treatment of adult patients with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with docetaxel.
